Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STI-3258 in Relapsed or Refractory Solid Tumors
NCT05060276Phase 1Withdrawn
- Sponsor
- Sorrento Therapeutics
- Start
- Dec 2022
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of ESG401 in solid tumor, sponsored by Sorrento Therapeutics. Primary endpoints: Incidence of adverse events by type, frequency, severity, and causality up to 24 months, Incidence of treatment-emergent adverse events up to 24 months and 4 more. Planned start Dec 2022; status: withdrawn.
02
Drugs
ESG401
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05060276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05060276.